Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11200803 | 0.85 | ALDH1A1 (0.56) | MEN1KMT2AMAPTRECQLTP53 | |
| SCHEMBL7341923 | 0.85 | KEAP1 (0.55) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL18656066 | 0.83 | CAPN1 (0.41) | MAPTCAPN1HTR2CHTR6FFAR1 | |
| SCHEMBL3941893 | 0.81 | SIRT2 (0.49) | MEN1KMT2AMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5677026 | 0.79 | ALDH1A1 (0.49) | MEN1KMT2ACAPN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL46647 | 0.79 | SMN1; SMN2 (0.58) | MEN1KMT2AMAPTTP53POLB | |
| SCHEMBL43642 | 0.77 | PLA2G10 (0.46) | MAPTCAPN1ALDH1A1SIGMAR1FFAR1 | |
| SCHEMBL22047275 | 0.77 | ALDH1A1 (0.60) | MAPTCAPN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL3053513 | 0.77 | TAAR1 (0.58) | MEN1KMT2AALDH1A1 | |
| SCHEMBL8021888 | 0.77 | MEN1 (0.43) | MEN1KMT2AMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
| US-9969710-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-15 | — | — | US | disclosed |
| US-20170081307-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081307-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 3661/4885KMT2A 855/4885MAPT 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.